Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib
Authors:
Open Access
- 30 July 2009
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 84 (10) , 657-660
Abstract
This clinical trial was conducted to determine the safety and efficacy of bortezomib retreatment in patients with multiple myeloma (MM) who had previously responded to bortezomib. Patients with progressive MM who had previously tolerated bortezomib as a single agent or in combination with other drugs, with a minimum of partial response (PR; ≥50% M‐protein reduction) for ≥4 months, who had not received intervening MM therapy, were retreated with bortezomib (days 1, 4, 8, and 11 of a 21‐day cycle) with a starting dose being the dose at which the patient ended the initial treatment. Patients were allowed to receive bortezomib on retreatment in combination with dexamethasone, thalidomide, or doxorubicin. Thirty‐two patients received bortezomib retreatment (most with added dexamethasone). The median treatment‐free interval (last dose of initial bortezomib treatment to first dose of retreatment) was 9.9 (range 2.5–34.0) months. The median duration of retreatment was 2.8 (<1–7.9) months; median total duration of bortezomib treatment was 6.7 (2.5–19.8) months. Based on the investigators' assessment of best response, the overall response rate (complete plus PR) was 50%. The median time from start of retreatment to progressive disease (PD) was 6.6 (95% confidence interval: 5.1–9.6) months. Thirteen patients (41%) experienced PN; bortezomib‐related SAEs were reported in four patients. Retreatment with bortezomib alone or in combination is effective and well tolerated in patients with MM who have responded to their initial bortezomib treatment. Am. J. Hematol., 2009.Keywords
This publication has 19 references indexed in Scilit:
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2008
- Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-upAnnals of Hematology, 2008
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood, 2007
- Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to ProgressionJournal of Clinical Oncology, 2007
- Beyond single-agent bortezomib: combination regimens in relapsed multiple myelomaCurrent Opinion in Oncology, 2006
- United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior TherapyClinical Cancer Research, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003